SARTORIUS STED BIO (EPA:DIM) Sartorius Stedim Biotech SA: Information on Document Availability
Transparency directive : regulatory news
|
Sartorius Stedim Biotech SA Aubagne, July 21, 2022
Information on Document AvailabilityThe report on the first half 2022 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at: It contains the following information:
A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.
Contact Petra Müller Head of Investor Relations +49 (0)551.308.6035 petra.mueller2@sartorius.com
Regulatory filing PDF file File: Sartorius Stedim Biotech - Rapport financier semestriel de janvier à juin 2022 |
| Language: | English |
| Company: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | info@sartorius-stedim.com |
| Internet: | www.sartorius-stedim.com |
| ISIN: | FR0013154002 |
| Euronext Ticker: | DIM |
| AMF Category: | Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly financial report |
| EQS News ID: | 1402595 |
| End of Announcement | EQS News Service |
1402595 21-Jul-2022 CET/CEST